Frontiers in Immunology (Jan 2023)
Systematic comparison of HIV-1 Envelope-specific IgG responses induced by different vaccination regimens: Can we steer IgG recognition towards regions of viral vulnerability?
- Augusta Horvath,
- Augusta Horvath,
- Lisa Rogers,
- Lisa Rogers,
- Georgios Pollakis,
- Olga Baranov,
- Olga Baranov,
- Nora Pieroth,
- Nora Pieroth,
- Sarah Joseph,
- Mkunde Chachage,
- Asli Heitzer,
- Lucas Maganga,
- Frank Msafiri,
- Agricola Joachim,
- Edna Viegas,
- Leigh-Anne Eller,
- Leigh-Anne Eller,
- Leigh-Anne Eller,
- Hannah Kibuuka,
- Supachai Rerks-Ngarm,
- Punnee Pitisuttithum,
- Sorachai Nitayapan,
- Jittima Dhitavat,
- Nakorn Premsri,
- Sarah Fidler,
- Robin J. Shattock,
- Merlin Lee Robb,
- Merlin Lee Robb,
- Jonathan Weber,
- Sheena McCormack,
- Patricia Jane Munseri,
- Eligius Lyamuya,
- Charlotta Nilsson,
- Charlotta Nilsson,
- Arne Kroidl,
- Arne Kroidl,
- Michael Hoelscher,
- Michael Hoelscher,
- Ralf Wagner,
- Ralf Wagner,
- Christof Geldmacher,
- Christof Geldmacher,
- Kathrin Held,
- Kathrin Held
Affiliations
- Augusta Horvath
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- Augusta Horvath
- German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany
- Lisa Rogers
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- Lisa Rogers
- German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany
- Georgios Pollakis
- Institute of Infection Veterinary and Ecological Sciences (IVES/CIMI), University of Liverpool, Liverpool, United Kingdom
- Olga Baranov
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- Olga Baranov
- German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany
- Nora Pieroth
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- Nora Pieroth
- German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany
- Sarah Joseph
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom
- Mkunde Chachage
- National Institute for Medical Research–Mbeya Medical Research Centre (NIMR-MMRC), Mbeya, Tanzania
- Asli Heitzer
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- Lucas Maganga
- National Institute for Medical Research–Mbeya Medical Research Centre (NIMR-MMRC), Mbeya, Tanzania
- Frank Msafiri
- Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
- Agricola Joachim
- Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
- Edna Viegas
- Instituto Nacional de Saúde, Maputo, Mozambique
- Leigh-Anne Eller
- United States Military HIV Research Program, Silver Spring, MD, United States
- Leigh-Anne Eller
- Makerere University Walter Reed Project, Kampala, Uganda
- Leigh-Anne Eller
- 0Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, United States
- Hannah Kibuuka
- Makerere University Walter Reed Project, Kampala, Uganda
- Supachai Rerks-Ngarm
- 1Department of Disease Control, Ministry of Public Health, Mueang Nonthaburi, Thailand
- Punnee Pitisuttithum
- 2Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
- Sorachai Nitayapan
- 3Armed Forces Research Institute of Medical Science, Bangkok, Thailand
- Jittima Dhitavat
- 2Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
- Nakorn Premsri
- 1Department of Disease Control, Ministry of Public Health, Mueang Nonthaburi, Thailand
- Sarah Fidler
- 4Department of Medicine, Imperial College London, London, United Kingdom
- Robin J. Shattock
- 4Department of Medicine, Imperial College London, London, United Kingdom
- Merlin Lee Robb
- United States Military HIV Research Program, Silver Spring, MD, United States
- Merlin Lee Robb
- 0Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, United States
- Jonathan Weber
- 4Department of Medicine, Imperial College London, London, United Kingdom
- Sheena McCormack
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom
- Patricia Jane Munseri
- Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
- Eligius Lyamuya
- Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
- Charlotta Nilsson
- 5Department of Laboratory Medicine, Karolinska Institute, Huddinge, Sweden
- Charlotta Nilsson
- 6The Public Health Agency of Sweden, Solna, Sweden
- Arne Kroidl
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- Arne Kroidl
- German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany
- Michael Hoelscher
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- Michael Hoelscher
- German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany
- Ralf Wagner
- 7Institute of Medical Microbiology and Hygiene, University Regensburg, Regensburg, Germany
- Ralf Wagner
- 8Institute of Clinical Microbiology and Hygiene; University Hospital Regensburg, Regensburg, Germany
- Christof Geldmacher
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- Christof Geldmacher
- German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany
- Kathrin Held
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- Kathrin Held
- German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany
- DOI
- https://doi.org/10.3389/fimmu.2022.1075606
- Journal volume & issue
-
Vol. 13
Abstract
Immunogens and vaccination regimens can influence patterns of immune-epitope recognition, steering them towards or away from epitopes of potential viral vulnerability. HIV-1 envelope (Env)-specific antibodies targeting variable region 2 (V2) or 3 (V3) correlated with protection during the RV144 trial, however, it was suggested that the immunodominant V3 region might divert antibody responses away from other relevant sites. We mapped IgG responses against linear Env epitopes in five clinical HIV vaccine trials, revealing a specific pattern of Env targeting for each regimen. Notable V2 responses were only induced in trials administering CRF01_AE based immunogens, but targeting of V3 was seen in all trials, with the soluble, trimeric CN54gp140 protein eliciting robust V3 recognition. Strong V3 targeting was linked to greater overall response, increased number of total recognised antigenic regions, and where present, stronger V2 recognition. Hence, strong induction of V3-specific antibodies did not negatively impact the targeting of other linear epitopes in this study, suggesting that the induction of antibodies against V3 and other regions of potential viral vulnerability need not be necessarily mutually exclusive.
Keywords